Equities analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce earnings of ($0.35) per share for the current quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.45). Lexicon Pharmaceuticals also posted earnings of ($0.35) per share in the same quarter last year. The firm is expected to report its next quarterly earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.55) to ($1.37). For the next year, analysts anticipate that the business will post earnings of ($0.89) per share, with EPS estimates ranging from ($1.17) to ($0.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company’s quarterly revenue was down 40.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.37) earnings per share.

Several brokerages have recently commented on LXRX. BidaskClub cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Wedbush reissued an “ourperform” rating and issued a $39.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday. Finally, ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $27.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 1.33% during midday trading on Tuesday, reaching $12.64. The company’s stock had a trading volume of 570,637 shares. The firm’s market cap is $1.33 billion. The firm has a 50 day moving average price of $14.52 and a 200-day moving average price of $15.30. Lexicon Pharmaceuticals has a 52 week low of $11.80 and a 52 week high of $19.62.

In related news, insider Lonnel Coats purchased 30,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was purchased at an average cost of $12.54 per share, with a total value of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.77% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. increased its stake in Lexicon Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 22,684 shares of the biopharmaceutical company’s stock valued at $325,000 after purchasing an additional 70 shares in the last quarter. Legal & General Group Plc increased its stake in Lexicon Pharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 465 shares in the last quarter. First Mercantile Trust Co. increased its stake in Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 1,227 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Lexicon Pharmaceuticals by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 36,417 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 1,291 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Lexicon Pharmaceuticals by 3.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 42,885 shares of the biopharmaceutical company’s stock valued at $705,000 after purchasing an additional 1,615 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Earnings of -$0.35 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/19/lexicon-pharmaceuticals-inc-lxrx-expected-to-announce-earnings-of-0-35-per-share.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.